Atzumi Shortage: What Providers and Prescribers Need to Know in 2026

Atzumi (dihydroergotamine [DHE] 5.2 mg nasal powder, Satsuma Pharmaceuticals) received FDA approval on April 30, 2025, representing the first dry powder intranasal DHE formulation. For neurologists, headache specialists, and primary care providers managing patients with migraine, Atzumi offers a meaningful clinical advancement — but its recent approval creates prescribing and access challenges that providers need to understand and proactively manage.

This guide covers the current access landscape for Atzumi in 2026, practical PA strategies, patient navigation tools, and how to handle situations where Atzumi cannot be obtained promptly.

Clinical Background: Why Atzumi Is a Meaningful Option

Dihydroergotamine has been a cornerstone of acute migraine management since its FDA approval in 1946. Unlike triptans, DHE acts on multiple receptor targets — 5-HT1B/1D/1F, alpha-adrenergic, and dopaminergic receptors — and inhibits CGRP-mediated cranial vasodilation. This multi-receptor profile makes DHE particularly effective for:

Patients with frequent migraine recurrence (DHE has a lower recurrence rate than triptans)

Triptan non-responders or triptan-contraindicated patients

Patients who present late in a migraine attack (DHE retains efficacy when administered after allodynia onset)

Status migrainosus and medication overuse headache

Atzumi's SMART (Simple MucoAdhesive Release Technology) platform represents a pharmacokinetic improvement over previous intranasal DHE formulations. In comparison to Migranal (liquid nasal spray), Atzumi achieves higher peak plasma concentrations and more consistent DHE delivery, with effective plasma levels reached within approximately 10 minutes. The ASCEND Phase 3 trial (n=334, 6,610 migraine attacks treated) reported 66.5% headache relief at 2 hours and 94.3% at 24 hours.

Current Access Challenges in 2026

As of 2026, Atzumi is not in an FDA-listed drug shortage. However, multiple structural access barriers affect patient access:

Prior Authorization Requirements

Most major pharmacy benefit managers (PBMs) implemented PA requirements for Atzumi at or shortly after its commercial launch. Caremark, for example, added Atzumi to its dihydroergotamine PA policy effective June 2025. Typical PA criteria include:

Diagnosis of migraine (ICD-10 G43.x)

Documentation of step therapy (trial of 2+ triptans, or clinical contraindication to triptans)

Quantity limits (typically 4 doses/7 days or 12 doses/30 days per prescribing information limits)

Submitting the PA simultaneously with the prescription is strongly recommended to minimize delays. Pre-populate PA forms with clinical rationale: specific triptans trialed and failed, clinical reason DHE is preferred (e.g., high recurrence migraine, triptan contraindication due to cardiovascular factors, status migrainosus history).

Pharmacy Stock and Distribution

Most retail pharmacies do not routinely stock Atzumi as of early 2026. Patients may be directed to specialty pharmacies by their insurer, or they may need to request that a retail pharmacy order Atzumi from their distributor. Advise patients to call ahead and allow 3–5 business days for a retail pharmacy to receive their first order from a wholesaler.

Cardiovascular Evaluation Requirement

The Atzumi prescribing information recommends a cardiovascular evaluation prior to initiation for all patients, and recommends that the first dose be administered in a healthcare setting for patients with coronary artery disease risk factors (hypertension, hypercholesterolemia, diabetes, smoking, males over 40, postmenopausal women). Factor this into your prescribing workflow — in-office first dose administration or ensuring the patient has had a recent, documented cardiovascular evaluation.

When to Consider Alternatives

If Atzumi access is substantially delayed, consider whether an alternative DHE formulation bridges the clinical need. Trudhesa (DHE mesylate precision nasal spray) has more established formulary coverage and is often available at retail or specialty pharmacies. Generic DHE nasal spray (Migranal generic) has lower cost and wider availability. CGRP antagonists (ubrogepant, rimegepant, zavegepant) are appropriate for patients who cannot use DHE due to cardiovascular risk factors.

Patient Navigation Resources

Directing patients to the right resources can significantly reduce the time to medication access. Recommend medfinder.com/providers — a service that calls pharmacies near the patient to identify which ones can fill Atzumi, so patients don't have to make multiple calls themselves.

Additionally, Satsuma Pharmaceuticals provides patient support services via satsumarx.com and their patient assistance line at 1-888-273-2480.

Prescribing Summary for Atzumi

Indication: Acute treatment of migraine with or without aura in adults

Dose: 5.2 mg (one device) intranasally; may repeat after ≥1 hour; max 10.4 mg/24h

Key contraindications: Strong CYP3A4 inhibitors, ischemic heart disease, uncontrolled hypertension, peripheral arterial disease, other 5-HT1 agonists or ergotamines within 24 hours, pregnancy

Boxed Warning: Serious/life-threatening peripheral ischemia with strong CYP3A4 inhibitors

DEA Schedule: Not a controlled substance

Outlook for 2026 and Beyond

Access barriers for Atzumi should ease throughout 2026 as the distribution network matures and formulary coverage stabilizes. As a newly-launched specialty drug, the friction is expected but manageable with proactive PA submission, patient navigation support, and bridging strategies when needed. For provider-specific resources on helping patients find Atzumi, visit medfinder.com/providers.